Anlotinib
Anlotinib is an oral multi-target tyrosine kinase inhibitor used in China for the treatment of certain advanced or metastatic cancers, including selected cases of non-small cell lung cancer, soft-tissue sarcoma, and medullary thyroid carcinoma, depending on the approved indication and treatment setting. It works by inhibiting signalling pathways involving vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), platelet-derived growth factor receptors (PDGFRs), and other kinases involved in tumour growth and angiogenesis. By interfering with tumour-cell signalling and the formation of new blood vessels, anlotinib can help slow cancer progression in eligible patients. It is administered orally according to the prescribed treatment schedule and should be managed by an oncology specialist. Common adverse effects include hypertension, fatigue, hand-foot skin reactions, diarrhoea, and loss of appetite. Serious risks may include bleeding, blood clots, impaired wound healing, proteinuria, and cardiac complications. Blood pressure, urine protein, liver function, and other relevant parameters should be monitored during treatment. Approved indications and availability vary by country.
Anlotinib was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Anlotinib, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Anlotinib from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Anlotinib, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
